Joinn Laboratories (06127) appoints Luo Xi and Gu Jingliang as executive directors.
Chao Yan New Drug (06127) announced the appointment of Ms. Luo Xi and Mr. Gu Jingliang as executive directors; ...
Joinn Laboratories (06127) announces the appointment of the following: (i) Ms. Luo Xi and Mr. Gu Jingliang as executive directors; (ii) Mr. Yang Fuquan, Mr. Yang Changyun, and Mr. Ying Fangtian as independent non-executive directors, effective from the conclusion of the extraordinary general meeting. In addition, from the date of the conclusion of the extraordinary general meeting, (i) Ms. Sun Yunxia will be appointed as a member of the company's remuneration and assessment committee and strategic committee; (ii) Ms. Luo Xi will be appointed as a member of the strategic committee; (iii) Mr. Yang Fuquan will be appointed as the chairman of the company's nomination committee and a member of the audit committee; (iv) Mr. Yang Changyun will be appointed as the chairman of the audit committee and a member of the remuneration and assessment committee; and (v) Mr. Ying Fangtian will be appointed as the chairman of the remuneration and assessment committee and a member of the strategic committee and nomination committee.
Related Articles

DAIDO GROUP (00544) issued a profit warning, expecting that the net loss attributable to shareholders in 2025 will be no less than approximately HK$72.1 million, an increase compared to the previous year.

KONG SUN HOLD (00295) expects a net loss of approximately 200 million to 240 million yuan in 2025.

INFINITY DEV (00640) spent HK$7.746 million on March 23 to repurchase 3.184 million shares.
DAIDO GROUP (00544) issued a profit warning, expecting that the net loss attributable to shareholders in 2025 will be no less than approximately HK$72.1 million, an increase compared to the previous year.

KONG SUN HOLD (00295) expects a net loss of approximately 200 million to 240 million yuan in 2025.

INFINITY DEV (00640) spent HK$7.746 million on March 23 to repurchase 3.184 million shares.






